Hidrocortizon Rompharm (Hydrocortisone)

Hidrocortizon Rompharm is indicated for several acute and chronic medical situations that require rapid glucocorticoid replacement or anti‑inflammatory effects.

• Treatment of primary or secondary adrenal insufficiency, including Addison’s disease.
• Management of severe allergic reactions such as anaphylaxis when intravenous therapy is required.
• Emergency treatment of septic, hypovolemic, or anaphylactic shock.
• Control of acute exacerbations of rheumatologic or dermatologic disorders (e.g., severe psoriasis, lupus flare).
• Adjunct therapy in certain oncologic protocols to mitigate chemotherapy‑induced inflammation.

• Hydrocortizon Rompharm delivers hydrocortisone, which binds to intracellular glucocorticoid receptors and translocates to the nucleus. The receptor‑ligand complex interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins such as annexin‑1 and suppressing pro‑inflammatory cytokines (e.g., IL‑1, IL‑6, TNF‑α). This genomic effect reduces vascular permeability, leukocyte migration, and immune activation, providing systemic glucocorticoid activity. Non‑genomic actions, including membrane‑stabilizing effects, may also contribute to rapid hemodynamic support in shock states.

Like other systemic glucocorticoids, hydrocortisone can produce a range of adverse reactions that vary with dose, duration, and individual susceptibility.

Common

• Transient increase in blood glucose levels.
• Mild gastrointestinal discomfort or dyspepsia.
• Fluid retention leading to peripheral edema.
• Mood changes such as irritability or insomnia.

Serious

• Severe hyperglycemia or new‑onset diabetes mellitus.
• Significant electrolyte disturbances, especially hypokalemia.
• Acute adrenal insufficiency on abrupt discontinuation.
• Increased risk of infection, including opportunistic pathogens.

Healthcare professionals should evaluate patient history and clinical status before initiating Hidrocortizon Rompharm to minimize avoidable risks.

• Assess for known hypersensitivity to hydrocortisone or any formulation excipients.
• Use caution in patients with uncontrolled diabetes, hypertension, or active peptic ulcer disease.
• Evaluate for underlying infections; glucocorticoids may mask fever or exacerbate bacterial growth.
• Monitor electrolyte balance, particularly potassium and sodium, during prolonged therapy.
• Consider tapering the dose when long‑term treatment is stopped to prevent adrenal crisis.
• Avoid use in patients with systemic fungal infections unless antifungal coverage is provided.

Hydrocortisone may alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; clinicians should review all current therapies.

Avoid

• Concurrent systemic CYP3A4 inducers (e.g., rifampin, phenytoin) that can reduce hydrocortisone exposure.
• Strong immunosuppressants such as high‑dose cyclosporine that increase infection risk when combined.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to additive gastrointestinal ulcer risk.
• Anticoagulants (e.g., warfarin) as glucocorticoids may affect coagulation parameters.
• Diabetic agents; hydrocortisone can raise blood glucose, requiring dose adjustment.
• Vaccines, especially live attenuated, because immunosuppression may diminish efficacy.